Severe hypoglycemia caused by a small dose of repaglinide and concurrent use of nilotinib and febuxostat in a patient with type 2 diabetes

Repaglinide, an oral hypoglycemic agent, is a short-acting insulin secretagogue. We describe a case, in which an extremely low dose of repaglinide caused severe hypoglycemia and novel drug interactions are suggested. A 71-year-old man with type 2 diabetes was taken to the hospital due to consciousne...

Full description

Saved in:
Bibliographic Details
Published in:Diabetology international 2020-10, Vol.11 (4), p.388-392
Main Authors: Komatsu, Hitomi, Enomoto, Mariko, Shiraishi, Hisashi, Morita, Yasuyo, Hashimoto, Daisuke, Nakayama, Shuichi, Funakoshi, Shogo, Hirano, Seiki, Terada, Yoshio, Miyamura, Mitsuhiko, Fujimoto, Shimpei
Format: Article
Language:English
Subjects:
Case Report
Diabetes
Diabetes mellitus (non-insulin dependent)
Drug dosages
Drug interactions
Endocrinology
Hypoglycemia
Inhibitor drugs
Insulin
Insulin secretion
Medicine
Medicine & Public Health
Metabolic Diseases
Oxidation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Repaglinide, an oral hypoglycemic agent, is a short-acting insulin secretagogue. We describe a case, in which an extremely low dose of repaglinide caused severe hypoglycemia and novel drug interactions are suggested. A 71-year-old man with type 2 diabetes was taken to the hospital due to consciousness disorder caused by severe hypoglycemia. He was taking repaglinide 0.25 mg once in the morning with nilotinib 400 mg/day and febuxostat 20 mg/day. Endogenous insulin secretion was not suppressed even in hypoglycemia. Detection of plasma repaglinide 10 h after administration in this case indicates delayed elimination of the agent, which might be derived from reduced hepatocyte uptake due to inhibitory effects of nilotinib on OATP1B1 and reduced oxidation of the agents by inhibitory effects of nilotinib, mainly on CYP3A4 activities, and of febuxostat on CYP2C8 activities. Repaglinide is eliminated by the liver, and is a short-acting insulin secretagogue with a good safety profile in patients with type 2 diabetes complicated by renal impairment, including elderly patients; however, its delayed elimination due to drug–drug interactions should be noted.
ISSN:2190-1678
2190-1686
DOI:10.1007/s13340-020-00434-w